More Stories

Informist, Thursday, Nov. 6, 2025

 

Please click here to read all liners published on this story

--Analysts saw Lupin Jul-Sept consol net profit INR 11.65 bln
--Lupin Jul-Sept consol net profit INR 14.78 bln
--Analysts saw Lupin Jul-Sept consol revenue INR 65.21 bln
--Lupin Jul-Sept consol revenue INR 70.48 bln
--Lupin Jul-Sept consol net profit INR 14.78 bln vs INR 8.53 bln year ago
--Lupin Jul-Sept consol revenue INR 70.48 bln vs INR 56.73 bln year ago
--Lupin Apr-Sept consol net profit INR 26.97 bln vs INR 16.54 bln year ago
--Lupin Apr-Sept consol revenue INR 133.16 bln vs INR 112.73 bln year ago
--Lupin Jul-Sept consol EBITDA INR 24.31 bln vs INR 13.83 bln year ago
--Lupin Jul-Sept consol EBITDA margin 35.6% vs 25.2% year ago
--Lupin Q2 consol mfg, other expenses INR 19.80 bln vs INR 16.67 bln year ago
--Lupin: Investment in R&D of INR 5.09 bln in Jul-Sept, 7.5% of sales
--Lupin: Capital expenditure was at INR 3.47 bln in Jul-Sept
--Lupin Jul-Sept India sales INR 20.78 bln vs INR 20.10 bln year ago
--Lupin Jul-Sept US sales INR 27.62 bln vs INR 18.75 bln year ago
--Lupin Jul-Sept API sales INR 2.57 bln vs INR 2.94 bln year ago
--Lupin Jul-Sept emerging markets sales INR 9.23 bln vs INR 6.35 bln

 

By Anand JC

 

MUMBAI - The consolidated net profit of Lupin Ltd. grew in strong double-digits year-on-year for the September quarter and exceeded analysts' projections. The company's revenue also beat consensus estimates, and grew at a nine-quarter high in the reporting quarter.

 

Lupin reported a consolidated net profit of INR 14.78 billion, up 73% on year. This is considerably higher than the consensus estimate of INR 11.65 billion.

 

The company's consolidated revenue for the September quarter stood at INR 70.48 billion, up just over 24% on year. Analysts had forecast Lupin's top line to grow around 15% on year to INR 65.21 billion. The pharmaceutical company's other operating income grew 23% on year to INR 2.16 billion in the reporting quarter. Lupin recorded other income of INR 900 million for the September quarter, more than double that of INR 423 million in the year-ago quarter. 

 

The consolidated earnings before interest, tax, depreciation, and amortisation of Lupin for the September quarter was INR 24.31 billion, up 76% on year. EBITDA margin was 35.6%, up from 25.2% in the year-ago quarter.

 

Consolidated expenses grew 10% on year to INR 51.31 billion. Other expenses, which form 39% of Lupin's expenses, grew 19% on year to INR 19.80 billion. Input costs remained under control as the cost of materials consumed grew only 2% on year to INR 11.39 billion.

 

The pharmaceutical major's tax outgo grew nearly threefold during the September quarter to INR 5.22 billion from INR 1.95 billion in the corresponding period a year ago. 

 

In Apr-Sept, Lupin's consolidated bottom line grew to INR 26.97 billion, up 63% from INR 16.54 billion in the year-ago period. Revenue from operations during the six months stood at INR 133.16 billion, up 18% on year. 

 

"We continue to see robust growth in revenues and EBITDA led by strong performance across the board, in the US, emerging markets, other developed markets and in India, supported by higher operational efficiencies and sustained investments," Lupin's Managing Director Nilesh Gupta said in a press release.

 

GEOGRAPHICAL PERFORMANCE

Lupin earned 40% of its revenue from the US business in the September quarter. Revenues from India business formed 30% while those from other developed markets and emerging markets were 12% and 14%, respectively.

 

While India revenue grew over 3% on year to INR 20.78 billion, Lupin's North America business reported a revenue of INR 28.72 billion, up 46% on year. More specifically, revenue from the US grew 47% on year to INR 27.62 billion. Revenue from Europe, West Asia and Africa business increased 24% on year while top line from the Asia Pacific business remained flat at INR 3.0 billion.

 

Lupin's revenue from emerging markets grew over 45% on year to INR 9.23 billion while top line from other developed markets grew nearly 19% on year to INR 8.12 billion. 

 

Revenue from Lupin's active pharmaceutical ingredients or API business fell 13% on year to INR 2.57 billion. This business formed only 4% of its total sales in the September quarter.

 

The company incurred a capital expenditure of INR 3.47 billion during the quarter, which was 5.1% of its overall sales. In the year-ago quarter, Lupin had spent INR 1.45 billion towards capital expenditure.

 

Lupin's gross profit for the September quarter was INR 50.07 billion, up 32% on year, with a gross margin of 73.3%. Manufacturing and other expenses were 29% of the company's sales at INR 19.80 billion. The company invested INR 5.09 billion, which was 7.5% of its sales, towards research and development during the quarter.

 

Lupin disclosed its September quarter earnings after the markets closed. Thursday, its shares ended 2.1% lower on the National Stock Exchange at INR 1,955.50.  End

 

Edited by Vandana Hingorani

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.